Fifth Third Wealth Advisors LLC Raises Stock Position in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)

Fifth Third Wealth Advisors LLC increased its holdings in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN - Free Report) by 118.1% during the fourth quarter, according to the company in its most recent disclosure with the SEC. The institutional investor owned 1,099 shares of the biopharmaceutical company's stock after purchasing an additional 595 shares during the period. Fifth Third Wealth Advisors LLC's holdings in Regeneron Pharmaceuticals were worth $783,000 as of its most recent SEC filing.

A number of other large investors also recently bought and sold shares of the business. Adirondack Trust Co. grew its position in shares of Regeneron Pharmaceuticals by 2.4% in the 3rd quarter. Adirondack Trust Co. now owns 431 shares of the biopharmaceutical company's stock worth $453,000 after buying an additional 10 shares during the last quarter. UMB Bank n.a. grew its holdings in Regeneron Pharmaceuticals by 1.1% in the third quarter. UMB Bank n.a. now owns 908 shares of the biopharmaceutical company's stock worth $955,000 after purchasing an additional 10 shares during the last quarter. Trust Co. of Vermont lifted its holdings in shares of Regeneron Pharmaceuticals by 8.3% during the 3rd quarter. Trust Co. of Vermont now owns 157 shares of the biopharmaceutical company's stock valued at $165,000 after purchasing an additional 12 shares during the last quarter. Brighton Jones LLC boosted its position in shares of Regeneron Pharmaceuticals by 1.5% in the 2nd quarter. Brighton Jones LLC now owns 920 shares of the biopharmaceutical company's stock worth $967,000 after purchasing an additional 14 shares in the last quarter. Finally, Nvwm LLC increased its position in Regeneron Pharmaceuticals by 1.4% during the 3rd quarter. Nvwm LLC now owns 988 shares of the biopharmaceutical company's stock valued at $1,039,000 after buying an additional 14 shares in the last quarter. Institutional investors own 83.31% of the company's stock.

Analysts Set New Price Targets

Several brokerages have weighed in on REGN. Wolfe Research started coverage on Regeneron Pharmaceuticals in a report on Friday, November 15th. They issued an "outperform" rating and a $1,150.00 price target for the company. Canaccord Genuity Group cut shares of Regeneron Pharmaceuticals from a "strong-buy" rating to a "hold" rating in a research note on Tuesday, December 17th. StockNews.com lowered shares of Regeneron Pharmaceuticals from a "strong-buy" rating to a "buy" rating in a research note on Monday, November 4th. Bank of America reiterated an "underperform" rating and set a $565.00 price objective on shares of Regeneron Pharmaceuticals in a research note on Tuesday, December 10th. Finally, Citigroup cut their target price on Regeneron Pharmaceuticals from $895.00 to $795.00 and set a "neutral" rating on the stock in a research report on Tuesday. One analyst has rated the stock with a sell rating, seven have given a hold rating, fifteen have given a buy rating and one has given a strong buy rating to the stock. According to MarketBeat.com, the company currently has a consensus rating of "Moderate Buy" and an average target price of $1,015.38.

Regeneron Pharmaceuticals Stock Performance

REGN traded down $11.65 on Friday, reaching $681.58. The stock had a trading volume of 1,107,622 shares, compared to its average volume of 870,528. The business's 50-day moving average price is $741.54 and its two-hundred day moving average price is $952.59. The company has a market cap of $74.90 billion, a P/E ratio of 16.87, a price-to-earnings-growth ratio of 1.60 and a beta of 0.10. Regeneron Pharmaceuticals, Inc. has a 12-month low of $666.25 and a 12-month high of $1,211.20. The company has a current ratio of 5.28, a quick ratio of 4.46 and a debt-to-equity ratio of 0.09.

About Regeneron Pharmaceuticals

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.